Commentary Open Access

Non-canonical CAR-T cell-related toxicities: Emerging strategies and challenges

Martina Canichella , Paolo de Fabritiis

CAR-T cell therapy revolutionized the treatment of patients with relapsed or refractory B-cell hematologic malignancies, substantially altering their prognosis. Alongside its remarkable efficacy, however, this approach is frequently accompanied by treatment-related toxicities. 

J Clin Exp Hematol, 2025, Volume 4, Issue 1, p17-21 | DOI: 10.46439/hematol.4.030